| |
golf property for sale in murcia
News and Information Article
Funding Will Support Clinical Development of Heart Failure Product
LA JOLLA, Calif., Dec. 7 // -- Celladon Corporation, a
biotechnology company developing treatments for heart failure and other
cardiovascular diseases, announced today that it had raised $30 million in a
Series B venture financing. The funding will enable Celladon to complete
preclinical testing and advance MYDICAR(TM), its product to improve calcium
handling in failing hearts, toward Phase 1/2 clinical trials.
New investors Kleiner Perkins Caufield & Byers and Domain Associates led
the round. Existing investors Enterprise Partners Venture Capital and Venrock
Associates also participated. Dr. Jesse Treu, General Partner of Domain, and
Joseph Lacob, General Partner of Kleiner Perkins, have joined Celladons Board
of Directors.
"The investment in Celladon by such high quality investors is testimony to
the strong potential of our product and the remarkable progress our team has
made since the company was founded 12 months ago," said Celladon Chairman Drew
Senyei. "In large animal models of heart failure, MYDICAR(TM) has shown
encouraging results. This Series B financing gives us an experienced board
and the resources to move the product toward the clinic."
"This financing will support development of Celladons MYDICAR(TM) gene
therapy system, which enhances SERCA2a, an important regulator of myocardial
contractility," said Krisztina Zsebo, Celladons CEO. The SERCA2a gene
construct is inserted in Adeno-Associated Virus (AAV) vectors and delivered to
the heart percutaneously using a closed-loop oxygenated system. Celladon
Corporation is collaborating with Targeted Genetics Corporation (Nasdaq: TGEN)
on AAV-based manufacturing and gene product development; and with The Baker
Heart Research Institute and V-Kardia, Inc. in development of a percutaneous
delivery system.
About Celladon
Celladon Corporation is a molecular cardiology company based in La Jolla,
California. The companys first product, MYDICAR(TM), combines a gene based
therapy with novel percutaneous delivery to enhance calcium cycling in the
hearts of patients with congestive heart failure.
| |
|
|
 |
golf property for sale in murcia |
|
|
|
|
|
|
|
|
|
Locations
